Merck discontinue development of CB-1 agonist taranabant

Merck has discontinued dvelopment of Cannabinoid 1 agonist Taranabant for Obesity due to adverse events

Merck and Japan Tobacco collaborate on Calcium Sensing Receptor antagonist

Merck have partnered with Japan Tobacco to commercialize JTT-305, a Ca sensing receptor antagonist with potential in the treatment of osteoporosis

Merck publish series of NPY Y5 receptor antagonists

Merck have published a series of trans -2-[3-oxospiro[isobenzofuran-1(3H),1’-cyclohexan]-4’-yl]benzimidazole NPY Y5 receptor antagonists

Merck publish series of Bradykinin B1 Receptor Antagonists

Merck have published a series of α-Hydroxy Amid Bradykinin B1 Receptor Antagonists

Merck publish series of Histamine H3 inverse agonists

Merck have published a paperon the synthesis and evaluation of a Spiro-isobenzofuranone Histamine H3 Receptor Inverse Agonists

Merck publish discovery of Nicotinic receptor partial agonist MK-0354

Merck have published the synthesis and preclinical data on nicotinic receptor partial agonist MK-0354

Merck publish series of Neuropeptide Y Y5 Receptor Antagonists

Merck have published a series of selective and orally active neuropeptide Y Y5 receptor antagonists.

Merck publish series of Quinazolinone Histamine H3 Receptor Inverse Agonists

Merck have published a new series of quinazolinone Histamine H3 Receptor Inverse Agonists

Mercks CGRP receptor antagonist telcagepant shows efficacy in migraine

Data from a Phase III trial show that Merck’s calcitonin gene-related peptide (CGRP) Receptor antagonist telcagepant (MK-0974) demonstrates migraine relief and has fewer adverse events than Zolmitriptan.

Merck/Schering withdraw Loratadine/Montelukast NDA and Terminate Collaboration

Schering-Plough and Merck have withdrawn the NDA for the loratadine/montelukast and announced that they will terminate the joint venture which was formed to develop and market a fixed-combination product that would combine loratadine and montelukast. This follows the receipt of a not-approvable letter from the FDA in April 2008.